Literature DB >> 23551679

Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.

Masatomo Taniguchi1, Masafumi Fukagawa, Naohiko Fujii, Takayuki Hamano, Tetsuo Shoji, Keitaro Yokoyama, Shigeru Nakai, Takashi Shigematsu, Kunitoshi Iseki, Yoshiharu Tsubakihara.   

Abstract

Mineral metabolism affects mortality in hemodialysis patients and is identified by imbalances in serum phosphate (P), calcium (Ca), and parathyroid hormone (PTH). We examined associations between annual mineral values (P, Ca, PTH) and mortality in a 3-year cohort (Dec 2006-2009) of 128,125 hemodialysis patients using three models, that is, baseline, time-dependent and time-average Cox models. We also examined associations between achieved Japanese guideline targets (P: 3.5-6.0 mg/dL, corrected Ca 8.4-10.0 mg/dL, intact PTH 60-180 mg/dL) and all-cause survival to elucidate which parameter should be controlled as a priority. High and low serum P (>6.0 or ≤ 3.5 mg/dL), high Ca (>9.5 mg/dL), higher PTH (>300 pg/mL) and lower PTH (≤ 60 pg/mL) were significantly associated with high mortality in all three models (P < 0.01). When we examined the association between combination of mineral targets and mortality, patients who achieved all targets simultaneously (20% of subjects, reference) showed lowest mortality. Those who achieved both P and Ca targets showed the same mortality as the reference group. Those who only met P target had a lower risk of death (hazard ratio = 1.17) compared to those that achieved Ca or PTH target (1.41, 1.47, respectively). As time of achieving P and Ca targets increased, all-cause mortalities diminished incrementally, significantly. Mineral metabolism disorder would lead to high mortality in prevalent hemodialysis patients. Among mineral values, P would be the strongest predictor for high mortality. Consistent achievement of P and Ca targets would lead to good survival.
© 2013 The Authors. Therapeutic Apheresis and Dialysis © 2013 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551679     DOI: 10.1111/1744-9987.12030

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  47 in total

Review 1.  Management of secondary hyperparathyroidism: how and why?

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2017-01-02       Impact factor: 2.801

2.  Anion Gap as a Determinant of Ionized Fraction of Divalent Cations in Hemodialysis Patients.

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Keiichi Kubota; Tatsufumi Oka; Satoshi Yamaguchi; Ayumi Matsumoto; Nobuhiro Hashimoto; Daisuke Mori; Yasue Obi; Isao Matsui; Yoshitaka Isaka
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 8.237

3.  Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis.

Authors:  Naomi Sasaki; Masataka Tsunoda; Ryota Ikee; Nobuo Hashimoto
Journal:  J Bone Miner Metab       Date:  2014-04-25       Impact factor: 2.626

4.  Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.

Authors:  Hirotaka Komaba; Masatomo Taniguchi; Atsushi Wada; Kunitoshi Iseki; Yoshiharu Tsubakihara; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

5.  An introduction to CKD-MBD research: restart for the future.

Authors:  Masafumi Fukagawa; Masaaki Inaba; Keitaro Yokoyama; Takashi Shigematsu; Ryoichi Ando; Ken-Ichi Miyamoto
Journal:  Clin Exp Nephrol       Date:  2017-03       Impact factor: 2.801

6.  Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.

Authors:  Yosuke Nakayama; Kaoru Ueda; Sho-Ichi Yamagishi; Miki Sugiyama; Chika Yoshida; Yuka Kurokawa; Nao Nakamura; Tomofumi Moriyama; Goh Kodama; Tomohisa Minezaki; Sakuya Ito; Akiko Nagata; Kensei Taguchi; Junko Yano; Yusuke Kaida; Kazutaka Shibatomi; Kei Fukami
Journal:  Clin Exp Nephrol       Date:  2017-04-18       Impact factor: 2.801

Review 7.  Mineral metabolism and cardiovascular disease in CKD.

Authors:  Hideki Fujii; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2017-01-06       Impact factor: 2.801

Review 8.  Management of phosphorus load in CKD patients.

Authors:  Yutaka Taketani; Fumihiko Koiwa; Keitaro Yokoyama
Journal:  Clin Exp Nephrol       Date:  2016-11-28       Impact factor: 2.801

Review 9.  Research on kidney and mineral metabolism in Japan: past, present, and future.

Authors:  Masahide Mizobuchi; Hiroaki Ogata; Fumihiko Koiwa; Eriko Kinugasa; Tadao Akizawa
Journal:  Clin Exp Nephrol       Date:  2016-12-22       Impact factor: 2.801

10.  Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.

Authors:  Hirotaka Komaba; Mia Wang; Masatomo Taniguchi; Suguru Yamamoto; Takanobu Nomura; Douglas E Schaubel; Abigail R Smith; Jarcy Zee; Angelo Karaboyas; Brian Bieber; Masafumi Fukagawa; Francesca Tentori
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.